Cancer-associated mucins: role in immune modulation and metastasis

Rakesh Bhatia, Shailendra K. Gautam, Andrew Cannon, Christopher Thompson, Bradley R. Hall, Abhijit Aithal, Kasturi Banerjee, Maneesh Jain, Joyce C Solheim, Sushil Kumar, Surinder Kumar Batra

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis. However, their aberrant overexpression and glycosylation in various malignancies facilitate oncogenic events from inception to metastasis. Mucin-associated sialyl-Tn (sTn) antigens bind to various receptors present on the dendritic cells (DCs), macrophages, and natural killer (NK) cells, resulting in overall immunosuppression by either receptor masking or inhibition of cytolytic activity. MUC1-mediated interaction of tumor cells with innate immune cells hampers cross-presentation of processed antigens on MHC class I molecules. MUC1 and MUC16 bind siglecs and mask Toll-like receptors (TLRs), respectively, on DCs promoting an immature DC phenotype that in turn reduces T cell effector functions. Mucins, such as MUC1, MUC2, MUC4, and MUC16, interact with or form aggregates with neutrophils, macrophages, and platelets, conferring protection to cancer cells during hematological dissemination and facilitate their spread and colonization to the metastatic sites. On the contrary, poor glycosylation of MUC1 and MUC4 at the tandem repeat region (TR) generates cancer-specific immunodominant epitopes. The presence of MUC16 neo-antigen-specific T cell clones and anti-MUC1 antibodies in cancer patients suggests that mucins can serve as potential targets for developing cancer therapeutics. The present review summarizes the molecular events involved in mucin-mediated immunomodulation, and metastasis, as well as the utility of mucins as targets for cancer immunotherapy and radioimmunotherapy.

Original languageEnglish (US)
Pages (from-to)223-236
Number of pages14
JournalCancer and Metastasis Reviews
Volume38
Issue number1-2
DOIs
StatePublished - Jun 15 2019

Fingerprint

Mucins
Neoplasm Metastasis
Neoplasms
Dendritic Cells
Glycosylation
Sialic Acid Binding Immunoglobulin-like Lectins
Macrophages
Cross-Priming
Radioimmunotherapy
T-Lymphocytes
Antigens
Immunodominant Epitopes
Tandem Repeat Sequences
Immunomodulation
Toll-Like Receptors
Masks
Cell Communication
Natural Killer Cells
Immunotherapy
Immunosuppression

Keywords

  • Cancer
  • Immunomodulation
  • Inflammation
  • Mucins
  • Vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Bhatia, R., Gautam, S. K., Cannon, A., Thompson, C., Hall, B. R., Aithal, A., ... Batra, S. K. (2019). Cancer-associated mucins: role in immune modulation and metastasis. Cancer and Metastasis Reviews, 38(1-2), 223-236. https://doi.org/10.1007/s10555-018-09775-0

Cancer-associated mucins : role in immune modulation and metastasis. / Bhatia, Rakesh; Gautam, Shailendra K.; Cannon, Andrew; Thompson, Christopher; Hall, Bradley R.; Aithal, Abhijit; Banerjee, Kasturi; Jain, Maneesh; Solheim, Joyce C; Kumar, Sushil; Batra, Surinder Kumar.

In: Cancer and Metastasis Reviews, Vol. 38, No. 1-2, 15.06.2019, p. 223-236.

Research output: Contribution to journalReview article

Bhatia, R, Gautam, SK, Cannon, A, Thompson, C, Hall, BR, Aithal, A, Banerjee, K, Jain, M, Solheim, JC, Kumar, S & Batra, SK 2019, 'Cancer-associated mucins: role in immune modulation and metastasis', Cancer and Metastasis Reviews, vol. 38, no. 1-2, pp. 223-236. https://doi.org/10.1007/s10555-018-09775-0
Bhatia R, Gautam SK, Cannon A, Thompson C, Hall BR, Aithal A et al. Cancer-associated mucins: role in immune modulation and metastasis. Cancer and Metastasis Reviews. 2019 Jun 15;38(1-2):223-236. https://doi.org/10.1007/s10555-018-09775-0
Bhatia, Rakesh ; Gautam, Shailendra K. ; Cannon, Andrew ; Thompson, Christopher ; Hall, Bradley R. ; Aithal, Abhijit ; Banerjee, Kasturi ; Jain, Maneesh ; Solheim, Joyce C ; Kumar, Sushil ; Batra, Surinder Kumar. / Cancer-associated mucins : role in immune modulation and metastasis. In: Cancer and Metastasis Reviews. 2019 ; Vol. 38, No. 1-2. pp. 223-236.
@article{e6f434ec541b45099944c4bf0c04a207,
title = "Cancer-associated mucins: role in immune modulation and metastasis",
abstract = "Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis. However, their aberrant overexpression and glycosylation in various malignancies facilitate oncogenic events from inception to metastasis. Mucin-associated sialyl-Tn (sTn) antigens bind to various receptors present on the dendritic cells (DCs), macrophages, and natural killer (NK) cells, resulting in overall immunosuppression by either receptor masking or inhibition of cytolytic activity. MUC1-mediated interaction of tumor cells with innate immune cells hampers cross-presentation of processed antigens on MHC class I molecules. MUC1 and MUC16 bind siglecs and mask Toll-like receptors (TLRs), respectively, on DCs promoting an immature DC phenotype that in turn reduces T cell effector functions. Mucins, such as MUC1, MUC2, MUC4, and MUC16, interact with or form aggregates with neutrophils, macrophages, and platelets, conferring protection to cancer cells during hematological dissemination and facilitate their spread and colonization to the metastatic sites. On the contrary, poor glycosylation of MUC1 and MUC4 at the tandem repeat region (TR) generates cancer-specific immunodominant epitopes. The presence of MUC16 neo-antigen-specific T cell clones and anti-MUC1 antibodies in cancer patients suggests that mucins can serve as potential targets for developing cancer therapeutics. The present review summarizes the molecular events involved in mucin-mediated immunomodulation, and metastasis, as well as the utility of mucins as targets for cancer immunotherapy and radioimmunotherapy.",
keywords = "Cancer, Immunomodulation, Inflammation, Mucins, Vaccine",
author = "Rakesh Bhatia and Gautam, {Shailendra K.} and Andrew Cannon and Christopher Thompson and Hall, {Bradley R.} and Abhijit Aithal and Kasturi Banerjee and Maneesh Jain and Solheim, {Joyce C} and Sushil Kumar and Batra, {Surinder Kumar}",
year = "2019",
month = "6",
day = "15",
doi = "10.1007/s10555-018-09775-0",
language = "English (US)",
volume = "38",
pages = "223--236",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "1-2",

}

TY - JOUR

T1 - Cancer-associated mucins

T2 - role in immune modulation and metastasis

AU - Bhatia, Rakesh

AU - Gautam, Shailendra K.

AU - Cannon, Andrew

AU - Thompson, Christopher

AU - Hall, Bradley R.

AU - Aithal, Abhijit

AU - Banerjee, Kasturi

AU - Jain, Maneesh

AU - Solheim, Joyce C

AU - Kumar, Sushil

AU - Batra, Surinder Kumar

PY - 2019/6/15

Y1 - 2019/6/15

N2 - Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis. However, their aberrant overexpression and glycosylation in various malignancies facilitate oncogenic events from inception to metastasis. Mucin-associated sialyl-Tn (sTn) antigens bind to various receptors present on the dendritic cells (DCs), macrophages, and natural killer (NK) cells, resulting in overall immunosuppression by either receptor masking or inhibition of cytolytic activity. MUC1-mediated interaction of tumor cells with innate immune cells hampers cross-presentation of processed antigens on MHC class I molecules. MUC1 and MUC16 bind siglecs and mask Toll-like receptors (TLRs), respectively, on DCs promoting an immature DC phenotype that in turn reduces T cell effector functions. Mucins, such as MUC1, MUC2, MUC4, and MUC16, interact with or form aggregates with neutrophils, macrophages, and platelets, conferring protection to cancer cells during hematological dissemination and facilitate their spread and colonization to the metastatic sites. On the contrary, poor glycosylation of MUC1 and MUC4 at the tandem repeat region (TR) generates cancer-specific immunodominant epitopes. The presence of MUC16 neo-antigen-specific T cell clones and anti-MUC1 antibodies in cancer patients suggests that mucins can serve as potential targets for developing cancer therapeutics. The present review summarizes the molecular events involved in mucin-mediated immunomodulation, and metastasis, as well as the utility of mucins as targets for cancer immunotherapy and radioimmunotherapy.

AB - Mucins (MUC) protect epithelial barriers from environmental insult to maintain homeostasis. However, their aberrant overexpression and glycosylation in various malignancies facilitate oncogenic events from inception to metastasis. Mucin-associated sialyl-Tn (sTn) antigens bind to various receptors present on the dendritic cells (DCs), macrophages, and natural killer (NK) cells, resulting in overall immunosuppression by either receptor masking or inhibition of cytolytic activity. MUC1-mediated interaction of tumor cells with innate immune cells hampers cross-presentation of processed antigens on MHC class I molecules. MUC1 and MUC16 bind siglecs and mask Toll-like receptors (TLRs), respectively, on DCs promoting an immature DC phenotype that in turn reduces T cell effector functions. Mucins, such as MUC1, MUC2, MUC4, and MUC16, interact with or form aggregates with neutrophils, macrophages, and platelets, conferring protection to cancer cells during hematological dissemination and facilitate their spread and colonization to the metastatic sites. On the contrary, poor glycosylation of MUC1 and MUC4 at the tandem repeat region (TR) generates cancer-specific immunodominant epitopes. The presence of MUC16 neo-antigen-specific T cell clones and anti-MUC1 antibodies in cancer patients suggests that mucins can serve as potential targets for developing cancer therapeutics. The present review summarizes the molecular events involved in mucin-mediated immunomodulation, and metastasis, as well as the utility of mucins as targets for cancer immunotherapy and radioimmunotherapy.

KW - Cancer

KW - Immunomodulation

KW - Inflammation

KW - Mucins

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85059669297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059669297&partnerID=8YFLogxK

U2 - 10.1007/s10555-018-09775-0

DO - 10.1007/s10555-018-09775-0

M3 - Review article

C2 - 30618016

AN - SCOPUS:85059669297

VL - 38

SP - 223

EP - 236

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 1-2

ER -